Nature's blueprint guides our systematic approach to discover highly selective protein degraders
To enable precision oncology through systematic discovery of selective degradation strategies aligned with tumor biology
Structural, functional, and disease-context data merged into a unified discovery framework.
AI models that rank degradation strategies by biological plausibility and selectivity potential.
Structural and biological context applied to filter and refine discovery candidates.
Cancer alignment and selectivity considered from the outset, not as an afterthought.
Most computational discovery platforms concentrate on target identification or ligand prediction.
Mithryon is designed to expand the degradation landscape itself.
That means searching for selective, cancer-aligned strategies beyond the industry's most reused biological mechanisms and translating those insights into actionable discovery direction.
April 2026
Systematic discovery of selective, cancer-aligned degradation strategies through integrated biology, AI, and experimental validation.
Learn More →Coming Soon
Partnering with oncology biotech and pharma teams for targeted degrader discovery collaborations.
Get in Touch →Expanding
Join us at the intersection of AI, structural biology, and protein degradation to expand therapeutic possibilities.
Join Us →Mithryon is a platform-plus-program company.
We work with oncology biotech and pharma teams through paid pilots, scoped discovery collaborations, and longer-term strategic partnerships.
Over time, the platform is designed to support partner-ready degrader programs with long-term shared upside.
To enable a new generation of precision degraders by systematically uncovering opportunities aligned with tumour biology.
Highly selective. Clinically meaningful.
Designed with patient safety in mind.
Precision degradation through systematic biology.
Mithryon's platform transforms how we discover selective degraders. By systematically mapping degradation landscapes and combining AI-driven insights with functional biology, we identify therapeutic opportunities that conventional approaches miss.
Comprehensively explore degradation space rather than relying on known mechanisms. Uncover selective strategies tailored to each target and disease context.
Functional biology informs computational models. Each experiment trains our system, creating a living feedback loop that accelerates discovery.
Biology-first approach grounded in human disease. Selectivity and efficacy considered from discovery outset, not as afterthought.
For pilot discussions, discovery collaborations, or investor conversations, get in touch.